Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,574 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Recruiting Phase 3 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo-Matching Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Withdrawn Phase 1 Interventional

Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI

NCT01605344
View directory record Official record
Conditions
Advanced Adenocarcinoma of the Colon or Rectum
Interventions
FOLFIRI., Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 3, 2026, 9:17 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Active, not recruiting Phase 3 Interventional

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy 1
Interventions
1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
2 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Gulf Breeze, Florida • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 4 Interventional Results available

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

NCT02344303
View directory record Official record
Conditions
Healthy
Interventions
TRV130, Moxifloxacin, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Nov 3, 2026, 9:17 AM EST
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Completed Not applicable Interventional

ROM Outcomes in Patients Undergoing a Primary TKA

NCT04217486
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Patient will be shown a photograph of their knee at 2 weeks postop, Patient will not be shown a photograph of their knee at 2 weeks postop
Other
Lead sponsor
University of Louisville
Other
Eligibility
22 Years to 89 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 3, 2026, 9:17 AM EST
Recruiting Phase 1 Interventional

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

NCT07729579
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Investigational drug, Photodynamic therapy
Drug · Device
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

NCT01530542
View directory record Official record
Conditions
Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders
Interventions
oxycodone hydrochloride, marketed oxycodone hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 2 Interventional

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

NCT07132983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Terminated Phase 2 Interventional Results available

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

NCT00899353
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions
Omega 3 Fatty Acid
Dietary Supplement
Lead sponsor
Marshall University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Nov 3, 2026, 9:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Breakfast on Hormone Responses and Cognitive Performance

NCT03005951
View directory record Official record
Conditions
Insulin Resistance
Interventions
A= Yes Breakfast, B=No Breakfast
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Nov 3, 2026, 9:17 AM EST
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 3, 2026, 9:17 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Phytosterols, Ezetimibe, and Cholesterol Metabolism

NCT00863265
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Ezetimibe, Phytosterols + ezetimibe, Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Nov 3, 2026, 9:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

NCT03077425
View directory record Official record
Conditions
Pediatric Obesity, Early Childhood Caries
Interventions
Enhanced Usual Care (EUC), Intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Months to 2 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
8
States / cities
East Windsor, New Jersey • New Brunswick, New Jersey • Jamaica, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Nov 3, 2026, 9:17 AM EST
Terminated Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04464564
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
46
States / cities
Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 3, 2026, 9:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Flexibility Training for Persistent Pain: Neuroimaging Pilot (COFLEX-i)

NCT03720821
View directory record Official record
Conditions
Chronic Pain, Knee Pain Chronic, Hip Pain Chronic, Back Pain
Interventions
Cognitive Training + fMRI
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

NCT00851721
View directory record Official record
Conditions
Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
4 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Nov 3, 2026, 9:17 AM EST
Not listed Not applicable Interventional

Impact of Standing Programs in Children With Spina Bifida: A Single Subject Design

NCT06419049
View directory record Official record
Conditions
Spina Bifida
Interventions
Altimate Medical EasyStand Bantam
Device
Lead sponsor
University of St. Augustine for Health Sciences
Other
Eligibility
5 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Nov 3, 2026, 9:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT00864448
View directory record Official record
Conditions
Healthy
Interventions
Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Nov 3, 2026, 9:17 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial on Rapid Immune Modulating Effects

NCT07206407
View directory record Official record
Conditions
Immune Surveillance
Interventions
Placebo, Nutraceutical blend
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 3, 2026, 9:17 AM EST